Groupe la Francaise Trims Stock Position in Danaher Corporation $DHR

Key Points

• Groupe la Francaise reduced its stake in Danaher Corporation (NYSE:DHR) by 19.3%, now holding 26,085 shares worth approximately $5.48 million.
• Danaher reported earnings of $1.80 per share for the latest quarter, exceeding estimates by $0.16, with revenue of $5.94 billion, a 3.4% increase year-over-year.
• Analysts have mixed outlooks on Danaher, with price targets ranging from $205.00 to $275.00, reflecting an average target of $247.61 and a consensus rating of "Moderate Buy".

Groupe la Francaise reduced its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 19.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 26,085 shares of the conglomerate's stock after selling 6,244 shares during the quarter. Groupe la Francaise's holdings in Danaher were worth $5,480,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in DHR. Bank Pictet & Cie Europe AG raised its position in Danaher by 22.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock worth $44,241,000 after purchasing an additional 35,730 shares during the period. First Trust Advisors LP raised its position in Danaher by 13.6% in the 4th quarter. First Trust Advisors LP now owns 37,854 shares of the conglomerate's stock worth $8,689,000 after purchasing an additional 4,519 shares during the period. MGO One Seven LLC raised its position in Danaher by 1.3% in the 4th quarter. MGO One Seven LLC now owns 4,285 shares of the conglomerate's stock worth $984,000 after purchasing an additional 53 shares during the period. Capital Analysts LLC raised its position in Danaher by 8.0% in the 4th quarter. Capital Analysts LLC now owns 17,258 shares of the conglomerate's stock worth $3,961,000 after purchasing an additional 1,273 shares during the period. Finally, Wills Financial Group Inc. raised its position in Danaher by 1.4% in the 4th quarter. Wills Financial Group Inc. now owns 41,797 shares of the conglomerate's stock worth $9,594,000 after purchasing an additional 578 shares during the period. 79.05% of the stock is owned by institutional investors.

Danaher Stock Up 0.2%

DHR traded up $0.42 during trading on Thursday, hitting $205.42. The stock had a trading volume of 2,510,877 shares, compared to its average volume of 4,179,342. The company has a market capitalization of $147.09 billion, a PE ratio of 43.71, a PEG ratio of 2.88 and a beta of 0.73. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The stock has a 50 day simple moving average of $201.23 and a two-hundred day simple moving average of $199.46.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same period in the previous year, the firm posted $1.72 earnings per share. The business's revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Insider Activity at Danaher

In related news, Director Teri List sold 2,778 shares of the firm's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 11.10% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on DHR. Barclays reissued an "overweight" rating and issued a $225.00 price objective (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Wall Street Zen raised shares of Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Wells Fargo & Company dropped their price objective on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Finally, Robert W. Baird increased their price objective on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $247.61.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.